Literature DB >> 32407191

Trends and Impact in Antimicrobial Resistance Among Bacteroides and Parabacteroides Species in 2007-2012 Compared to 2013-2017.

Marta Kierzkowska1,2, Anna Majewska1,2, Grazyna Mlynarczyk1,2.   

Abstract

Purpose: The aim of this study was to analyze the susceptibility of Bacteroides and Parabacteroides spp. strains, isolated from patients hospitalized in the clinical hospital in Poland to penicillin, amoxicillin with clavulanic acid, imipenem, clindamycin, and metronidazole.
Methods: We analyzed susceptibility of 476 isolates to routinely use for the treatment of anaerobic bacterial infections antibiotics. E test method was used to determining the minimal inhibitory concentration values. To show the trend of drug resistance, we compared data from two periods within the years 2003-2017.
Results: Research results indicate that the problem of resistance is mainly related to strains belonging to non-fragilis Bacteroides. In the analyzed periods, there was an increase in the percentage of clindamycin-resistant isolates (35.21% vs. 53.33%), amoxicillin/clavulanic acid (2.83% vs. 8.15%), and imipenem (1.41% vs. 3.7%). In isolates belonging to Parabacteroides distasonis, we observed a constant high (∼50%) percentage of clindamycin-resistant strains. The overwhelming majority of B. fragilis strains were resistant to penicillin (>95%) and about 20% of the isolates were not susceptible to clindamycin. Conclusions: Clindamycin, due to the high and increasing percentage of resistant strains, may not be a good choice in the empirical therapy of infections caused by Bacteroides and P. distasonis. Our study highlighted the importance of a routine or at least periodic monitoring of antimicrobial susceptibility of anaerobic Gram-negative bacilli, providing important information for appropriate therapy. The study shows that infection caused (or suspected of being caused) by Bacteroides and Parabacteroides spp. can be empirically treated with metronidazole or imipenem.

Entities:  

Keywords:  Bacteroides; anaerobic bacteria; antimicrobial resistance; clindamycin

Year:  2020        PMID: 32407191     DOI: 10.1089/mdr.2019.0462

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  6 in total

Review 1.  Time for Some Group Therapy: Update on Identification, Antimicrobial Resistance, Taxonomy, and Clinical Significance of the Bacteroides fragilis Group.

Authors:  Sophonie Jean; Miranda J Wallace; Gautam Dantas; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2022-06-14       Impact factor: 11.677

2.  Assessing Gut Microbiota in an Infant with Congenital Propionic Acidemia before and after Probiotic Supplementation.

Authors:  Andrea Bordugo; Elisa Salvetti; Giulia Rodella; Michele Piazza; Alice Dianin; Angela Amoruso; Giorgio Piacentini; Marco Pane; Sandra Torriani; Nicola Vitulo; Giovanna E Felis
Journal:  Microorganisms       Date:  2021-12-16

Review 3.  Parabacteroides distasonis: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health.

Authors:  Jessica C Ezeji; Daven K Sarikonda; Austin Hopperton; Hailey L Erkkila; Daniel E Cohen; Sandra P Martinez; Fabio Cominelli; Tomomi Kuwahara; Armand E K Dichosa; Caryn E Good; Michael R Jacobs; Mikhail Khoretonenko; Alida Veloo; Alexander Rodriguez-Palacios
Journal:  Gut Microbes       Date:  2021 Jan-Dec

4.  Comparison of Phenotypic and Genotypic Patterns of Antimicrobial-Resistant Bacteroides fragilis Group Isolated from Healthy Individuals in Vietnam and Japan.

Authors:  Hanh Vu; Masahiro Hayashi; Thang Nam Nguyen; Diep Thi Khong; Hoa Thi Tran; Yoshimasa Yamamoto; Kaori Tanaka
Journal:  Infect Drug Resist       Date:  2021-12-11       Impact factor: 4.003

Review 5.  Gut Microbiota in Nutrition and Health with a Special Focus on Specific Bacterial Clusters.

Authors:  Lucas R F Bresser; Marcus C de Goffau; Evgeni Levin; Max Nieuwdorp
Journal:  Cells       Date:  2022-09-30       Impact factor: 7.666

6.  Antimicrobial Susceptibility of Clinical Oral Isolates of Actinomyces spp.

Authors:  Alexandra Wolff; Arne C Rodloff; Paul Vielkind; Toralf Borgmann; Catalina-Suzana Stingu
Journal:  Microorganisms       Date:  2022-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.